Search NLS News

The robust financial ecosystem surrounding Nordic life sciences offers an edge of resilience in a global arena that’s moving into a bear market. Over the last few years the Nordic financial landscape has seen a boost of new actors specializing in life sciences entering the stage, with the establishment of several VC funds and angel […]

The Board of Directors of the company has appointed Monica Shaw as Chief Executive Officer, CEO, of Oncopeptides. Shaw replaces Jakob Lindberg, who has been the CEO since November 15, 2021. Lindberg assumes his previous position as Chief Scientific Officer. A transformational year The leadership changes follow a transformational year for Oncopeptides, when Pepaxti, was […]

Norway’s first innovation district is taking shape in Oslo and when completed, the capital will also host the country’s largest life science building. Norway’s and especially Oslo’s life science sector is on the rise. Oslo is home to the largest hospital in the Nordic region, top international research groups in cancer and immunology and a […]

Per Alfredsson has been appointed new Chief Executive Officer of AstraZeneca AB. Per Alfredsson took over the role after Katarina Ageborg on January 9th. He will maintain his role as Senior Vice President for Biologics Operations and will continue to lead the company’s global production network for biologics. Katarina Ageborg will retire from AstraZeneca after […]

The two companies have entered into a collaboration agreement regarding the continued development of Zyneyro’s peptide- and AAV-based treatment of chronic pain conditions. The agreement with Zyneyro is a cooperation agreement that means that Zyneyro and CombiGene share the project’s costs and revenues equally. “The concept of being able to give the pain-relieving peptide directly […]

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, a US-based clinical-stage biopharmaceutical company, focused on developing novel treatments for resistant and uncontrolled hypertension as well as chronic kidney disease. The acquisition will bolster AstraZeneca’s cardiorenal pipeline by adding CinCor’s candidate drug, baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for blood pressure lowering […]

Evaxion Biotech has announced that the U.S. Food and Drug Administration determined that the company may proceed with its Phase 2b clinical trial of EVX-01. In November 2022, the company submitted an Investigational New Drug Application (IND) along with a Fast Track designation application to the FDA for a Phase 2b clinical trial of EVX-01 […]

BioArctic’s partner Eisai has announced that under the Accelerated Approval pathway the U.S. Food and Drug Administration (FDA) has approved lecanemab-irmb (Brand Name in the U.S.: LEQEMBI) for the treatment of Alzheimer’s disease. The approval concerns lecanemab-irmb (Brand Name in the U.S.: LEQEMBI) 100 mg/mL injection for intravenous use, a humanized immunoglobulin gamma 1 (IgG1) […]

SwedenBIO has appointed the co-founder and operational manager of Sprint Bioscience, Jessica Martinsson, as its new Director General. “With her entrepreneurial experience and co-founder of a life science company, SwedenBIO will gain a leadership that will drive the industry’s development further. Jessica’s knowledge within drug development in both small and large companies as well as […]

Alligator Bioscience has announced an expansion to its research collaboration and license agreement with Orion Corporation, to discover and develop together new bispecific antibody cancer therapeutics. The collaboration has been expanded to add the development of a second bispecific antibody using Alligator’s bispecific RUBY platform, where Alligator will provide validated monospecific binders for one target […]